Brainsway

Indonesia
Sumbul, North Sumatra, Indonesia, 91451

Company profile

Brainsway company profile

Brainsway's patented breakthrough technology launches a new era in brain disorder treatment. A non-invasive, yet highly effective solution, Brainsway can make a difference in the wellbeing and health of millions of patients worldwide. Brainsway's technology releases millions of patients from a bleak cycle of insufficiently effective treatments and unpleasant side effects. Brainsway's treatment was approved by the FDA for Major Depressive Disorder patients*. The technology is also safe, with no systemic effects or long-term side effects, and highly convenient, requiring only brief daily sessions over a couple of weeks. Brainsway's technology has already been applied in thousands of cases worldwide in the framework of clinical studies. It has also been enthusiastically embraced by leading research institutions worldwide, with over 60 clinical trials performed. Brainsway technology is based on a patent registered by the U.S. National Institutes of Health (NIH). Brainsway is dedicated to research and continuously explores treatments for a variety of brain disorders.

Business identity

Contact email
[email protected]
Phone number
+972 8552003867
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Revenue range
$1M-$10M
Founded
2003-01-01, Year

Headquarters

Postal code
91451
Country code
ID
Continent
Asia

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
5
Total equity funding
$85.5M
Last funding
Post IPO Equity / $20M / 2024-09-30
Last equity funding
Post IPO Equity / $20M
Investors
5
Lead investors
2
Founders
5
Articles
147
Exited on
2007-01-04

Founders and investors

Founders

Avner HagaiAvraham ZangenDavid ZacutUzi SoferYiftach Roth

Lead investors

Valor Equity PartnersYelin Lapidot Investment House

Investors

Cybele HoldingsIBI Investment HousePhoenix FinancialValor Equity PartnersYelin Lapidot Investment House